Profile data is unavailable for this security.
About the company
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is a China-based company mainly engaged in the production and sale of vaccine products. The Company operates two segments. Diagnostic segment produces and sells in vitro diagnostic reagents and instruments suitable for in vitro diagnostic reagent testing. Vaccine segment produces and sells vaccines. The in vitro diagnostic reagents mainly include enzyme-linked immunosorbent assay reagents, colloidal gold diagnostic reagents, biochemical diagnostic reagents, chemiluminescent diagnostic reagents, and others. The in vitro diagnostic instruments include fully automatic chemiluminescent immunoassay analyzers, dry fluorescent immunoassay analyzers, fully automatic nucleic acid purification, and others. The vaccines mainly include hepatitis E vaccine, bivalent human papillomavirus (HPV) vaccine and nasal spray COVID-19 vaccine.
- Revenue in CNY (TTM)2.49bn
- Net income in CNY-294.04m
- Incorporated1991
- Employees3.84k
- LocationBeijing Wantai Biological Pharmacy Enterprise Co LtdNo.31 Science Park RoadChangping DistrictBEIJING 102206ChinaCHN
- Phone+86 1 059528820
- Fax+86 1 089705849
- Websitehttps://www.ystwt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Tongrentang Co Ltd | 17.96bn | 1.63bn | 56.09bn | 16.78k | 34.45 | 4.32 | -- | 3.12 | 1.19 | 1.19 | 13.09 | 9.46 | 0.5912 | 1.08 | 11.14 | 1,070,467.00 | 7.88 | 8.20 | 15.63 | 16.17 | 44.48 | 46.59 | 13.33 | 13.33 | 1.58 | -- | 0.1765 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Shanghai Fosun Pharmaceutical (Group) | 41.61bn | 2.11bn | 65.23bn | 40.37k | 34.62 | 1.54 | -- | 1.57 | 0.7883 | 0.7883 | 15.54 | 17.71 | 0.3682 | 2.86 | 5.10 | 1,030,748.00 | 2.44 | 4.31 | 4.18 | 7.01 | 47.10 | 50.71 | 6.63 | 10.65 | 0.7221 | -- | 0.3755 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.85bn | 3.80bn | 80.56bn | 2.09k | 21.20 | 18.99 | -- | 13.78 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 2.49bn | -294.04m | 93.53bn | 3.84k | -- | 7.53 | -- | 37.56 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Merchants Fund Management Co., Ltd.as of 30 Sep 2023 | 6.77m | 0.54% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 4.81m | 0.38% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 3.15m | 0.25% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 2.59m | 0.21% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 2.29m | 0.18% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.25m | 0.18% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 2.23m | 0.18% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2024 | 2.21m | 0.18% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.01m | 0.16% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.17m | 0.09% |
